结晶氯化锂 | 16712-20-2

• 物质功能分类: 无机化工 - 无机盐 - 金属卤化物及卤酸盐
• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 碱金属盐
• 中文名称: 结晶氯化锂
• 中文别名: 水合氯化锂；氯化锂；一水合氯化锂；氯化锂一水合物；氯化锂单水合物
• 英文名称: lithium chloride monohydrate
• 英文别名: lithium chloride hydrate；lithium;chloride;hydrate
• CAS: 16712-20-2
• 化学式: Cl*H₂O*Li
• 分子量: 60.4093
• InChiKey: VXJIMUZIBHBWBV-UHFFFAOYSA-M

物化性质

• 熔点：
  >98°C -H₂O
• 沸点：
  1382℃
• 密度：
  1.78
• 溶解度：
  极易溶于H2O
• 稳定性/保质期：
  - 常温常压下稳定。 - 应避免接触：水分或潮湿、氧化物、光、酸及卤素化合物。

计算性质

• 辛醇/水分配系数(LogP)：
  -6.82
• 重原子数：
  3
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xn
• 安全说明：
  S26
• 危险类别码：
  R22
• WGK Germany：
  1
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

---

Section 1: Product Identification
Chemical Name: Lithium chloride hydrate (99.996%-Li) PURATREM
CAS Registry Number: 16712-20-2
Formula: LiCl.XH2O
EINECS Number: none
Chemical Family: metal halide
Synonym: Lithium monochloride hydrate

---

Section 2: Composition and Information on Ingredients
Ingredient CAS Number Percent ACGIH (TWA) OSHA (PEL)
Title Compound 16712-20-2 100% no data no data

---

Section 3: Hazards Identification
Emergency Overview: Irritating to skin, eyes and respiratory tract. Harmful in contact with skin and if swallowed.
Primary Routes of Exposure: Ingestion, Inhalation of dust.
Eye Contact: Slight to mild irritant of the eyes.
Skin Contact: Slight to mild irritant of the skin.
Inhalation: Dust is irritating to the nose, mucous membranes and respiratory tract.
Ingestion: Ingestion may lead to dizziness, abdominal cramps, vomiting, bloody diarrhea, weakness, and convulsions.
Harmful in contact with skin and if swallowed. Irritating to skin, eyes and respiratory tract. May cause harm to
Acute Health Affects:
the unborn child and brestfed babies.
Chronic Health Affects: May cause heritable genetic damage. Possible risk of impaired fertility.
NTP: No
IARC: No
OSHA: No

---

SECTION 4: First Aid Measures
Immediately flush the eyes with copious amounts of water for at least 10-15 minutes. A victim may need
Eye Exposure:
assistance in keeping their eye lids open. Get immediate medical attention.
Wash the affected area with water. Remove contaminated clothes if necessary. Seek medical assistance if
Skin Exposure:
irritation persists.
Remove the victim to fresh air. Closely monitor the victim for signs of respiratory problems, such as difficulty
Inhalation:
in breathing, coughing, wheezing, or pain. In such cases seek immediate medical assistance.
Seek medical attention immediately. Keep the victim calm. Give the victim water (only if conscious). Induce
Ingestion:
vomiting only if directed by medical personnel.

---

SECTION 5: Fire Fighting Measures
Flash Point: not applicable
Autoignition Temperature: none
Explosion Limits: none
Extinguishing Medium: None. Material is non-flammable.
Special Fire Fighting Procedures: No special fire fighting procedures required.
Hazardous Combustion and none
Decomposion Products:
Unusual Fire or Explosion Hazards: No unusual fire or explosion hazards.

---

SECTION 6: Accidental Release Measures
To avoid raising dust, small spills may be mixed with diatomaceous earth, sand, vermiculite or other suitable
Spill and Leak Procedures:
inert material and swept up.

---

SECTION 7: Handling and Storage
Handling and Storage: Store solid in a tightly sealed container.

---

SECTION 8: Exposure Controls and Personal Protection
Eye Protection: Always wear approved safety glasses when handling a chemical substance in the laboratory.
Skin Protection: Wear protective clothing and gloves. Consult with glove manufacturer to determine the proper type of glove.
Ventilation: Material may form a fine dust. If possible, handle the material in an efficient fume hood.
If in form of fine dust and ventilation is not available a respirator should be worn. The use of respirators
Respirator:
requires a Respirator Protection Program to be in compliance with 29 CFR 1910.134.
Ventilation: Material may form a fine dust. If possible, handle the material in an efficient fume hood.
Additional Protection: No additional protection required.

---

SECTION 9: Physical and Chemical Properties
Color and Form: white xtl.
Molecular Weight: 42.39
Melting Point: no data
Boiling Point: no data
Vapor Pressure: no data
Specific Gravity: no data
Odor: none
Solubility in Water:

---

SECTION 10: Stability and Reactivity
Stability: air and moisture stable
Hazardous Polymerization: no hazardous polymerization
Conditions to Avoid: none
Incompatibility: none
Decomposition Products: water, metal chloride

---

SECTION 11: Toxicological Information
RTECS Data: No information available in the RTECS files.
Carcinogenic Effects: no data
Mutagenic Effects: mutagen (data equated to anhydrous form)
Tetratogenic Effects: reproductive effector (data equated to anhydrous form)

---

SECTION 12: Ecological Information
Ecological Information: No information available

---

SECTION 13: Disposal Considerations
Disposal: Dispose of according to local, state and federal regulations.

---

SECTION 14: Transportation
Shipping Name (CFR): Non-hazardous
Hazard Class (CFR): NA
Additional Hazard Class (CFR): NA
Packaging Group (CFR): NA
UN ID Number (CFR): NA
Shipping Name (IATA): Non-hazardous
Hazard Class (IATA): NA
Additional Hazard Class (IATA): NA
Packaging Group (IATA): NA
UN ID Number (IATA): NA

---

SECTION 15: Regulatory Information
TSCA: Not listed in the TSCA inventory.
SARA (Title 313): Title compound not listed.
Second Ingredient: none

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

氯化锂是一种白色晶体，具有NaCl型面心晶格（边长a=0.513nm），熔点为605℃，沸点为136℃。它具有很强的吸湿性，并能溶于甲醇、乙醇、吡啶、乙醚和丙酮，微溶于液氨。氯化锂一水合物是由氯化锂与水组成的化合物。

用途

由于氯化锂及其衍生产品在受控核聚变反应、铝锂合金、锂离子电池以及光通信中的非线性光学材料等行业需求的大幅增长，对原料氯化锂的需求也随之增加。这种趋势越来越明显，使得氯化锂的生产前景更加广阔。

反应信息

• 作为反应物：
  描述：

  4-溴-N-Boc-DL-苯丙氨酸甲酯 、 结晶氯化锂 、 硼氢化钠 在 4-溴-N-Boc-DL-苯丙氨酸甲酯 作用下， 以 乙醇 、 四氢呋喃 为溶剂， 反应 16.0h， 以to give 3f as a white solid (13 g, 94% yield)的产率得到tert-butyl (1-(4-bromophenyl)-3-hydroxypropan-2-yl)carbamate
  参考文献：
  名称：

  Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease

  摘要：

  本发明提供了孤儿核受体RORγ的调节剂，并通过向需要治疗RORγ介导的疾病的人类或哺乳动物施用这些新型RORγ调节剂的方法来治疗这些疾病。具体而言，本发明提供了式（1）及其对映体、非对映体异构体、互变异构体、溶剂化物和药学上可接受的盐的化合物。

  公开号：

  US08940722B2
• 作为试剂：
  描述：

  3-(4-chloro-2-fluoro-5-methoxyphenyl)-4-methyl-5-cyano-1-methyl-[1H]-pyrazole 在 结晶氯化锂 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 96.0h， 以60.9%的产率得到3-(4-chloro-2-fluoro-5-hydroksyphenyl)-4-methyl-5-cyano-1-methyl-[1H]-pyrazole
  参考文献：
  名称：

  Pyrazde herbicides

  摘要：

  化合物I的公式中，其中R1为C1-C4烷基；R2为氰基或NH2C(S)；R3为氢，C1-C4烷基，C1-C4卤代烷基，C3-或C4烯基，C3-或C4炔基，C3-C8卤代烯基，NC-CH2-，HOC(O)-CH2-或C1-C4烷氧基-C(O)-CH2-；W是一个基团；R4至R6、R60、R61、R70、X1、X2、n1和A1-B1如权利要求1所定义，以及式中除了化合物的公式之外的吡唑氧化物、农业上可接受的盐和立体异构体，具有良好的选择性除草性能，可用于前后除草。描述了这些化合物的制备及其作为除草活性成分的使用。

  公开号：

  US06339046B1

文献信息

• Process for the preparation of cyclopropane derivatives, intermediates
  申请人：Imperial Chemical Industries Limited

  公开号：US04284582A1

  公开（公告）日：1981-08-18

  Compounds of formula: ##STR1## wherein both groups X are chlorine, bromine or trifluoromethyl, or one X is chlorine or bromine and the other is trifluoromethyl, and Y is --CN or --COOR in which R is an alkyl group, are obtained by (A) reacting a compound of the formula: ##STR2## wherein X.sup.1 is chlorine or bromine, with a compound of the formula: X.sub.2 C.dbd.CH--CH.dbd.C(CH.sub.3).sub.2 in the presence of metallic copper or at least one copper salt and a base, or (B) reacting a compound of the formula: Y--CH.sub.2 --CN with a compound of the formula: X.sub.2 C.dbd.CH--CH.dbd.C(CH.sub.3).sub.2 and chlorine or bromine, in the presence of at least one reducible copper salt and a base, or (C) reacting a compound of formula: X--CH.sub.2 --CN with a compound of the formula: ##STR3## wherein X.sup.1 is chlorine or bromine, in the presence of at least one copper salt. The compounds are intermediates in the synthesis of pyrethroid insecticides.

  公式为：##STR1##的化合物，其中两个X基团为氯、溴或三氟甲基，或一个X为氯或溴，另一个为三氟甲基，而Y为--CN或--COOR，其中R为烷基，通过以下方法得到：（A）将公式为##STR2##的化合物，其中X.sup.1为氯或溴，与化合物X.sub.2C.dbd.CH--CH.dbd.C(CH.sub.3).sub.2在金属铜或至少一种铜盐和碱的存在下反应，或（B）将公式为Y--CH.sub.2--CN的化合物与化合物X.sub.2C.dbd.CH--CH.dbd.C(CH.sub.3).sub.2和氯或溴在至少一种可还原铜盐和碱的存在下反应，或（C）在至少一种铜盐的存在下，将公式为X--CH.sub.2--CN的化合物与公式为##STR3##的化合物，其中X.sup.1为氯或溴，反应。这些化合物是拟除虫菊酯杀虫剂合成的中间体。
• Dihydro-benzo [b] [1,4] diazepin-2-one derivatives
  申请人：——

  公开号：US20020198197A1

  公开（公告）日：2002-12-26

  This invention is a dihydro-benzo [b] [1,4] diazepin-2-one derivative of the formula 1 wherein R 1 , R 2 , R 3 and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation and a method of treatment or prevention of acute and/or chronic neurological disorders by administering an effective amount of the compound of formula I or a pharmaceuticall acceptable salt thereof.

  这项发明是一种公式1中R1、R2、R3和Y如规范中定义的二氢苯并[b][1,4]二氮杂吡啶-2-酮衍生物。该发明包括含有这些化合物的药物组合物，制备这些化合物的方法以及通过给予公式I的化合物或其药学上可接受的盐的有效量来治疗或预防急性和/或慢性神经系统疾病的方法。
• Preparation cyano substituted cyclopropane
  申请人：Imperial Chemical Industries Limited

  公开号：US04118412A1

  公开（公告）日：1978-10-03

  A process for the preparation of cyclopropane compounds which comprises reacting a compound of formula: Y--CH.sub.2 --CN with a diene of formula: CX.sub.2 =CH--CH=C(CH.sub.3).sub.2 in the presence of at least one reducible copper salt, X being chlorine or bromine and Y being cyano, alkoxycarbonyl containing up to four carbon atoms in the alkoxy moiety, benzyloxycarbonyl, phenoxybenzyloxycarbonyl or 2,2-dichlorovinyloxybenzyloxycarbonyl.

  一种制备环丙烷化合物的方法，包括在至少一种可还原的铜盐的存在下，将式为Y-CH2-CN的化合物与式为CX2=CH-CH=C(CH3)2的二烯反应，其中X为氯或溴，Y为氰基，含有最多四个碳原子的烷氧羰基，苄氧羰基，苯氧基苄氧羰基或2,2-二氯乙烯氧基苄氧羰基。
• Dihydro-benzo [B] [1,4] diazepin-2-one derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06548495B2

  公开（公告）日：2003-04-15

  This invention is a dihydro-benzo[b][1,4]diazepin-2-one derivative of the formula wherein R1, R2, R3 and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation and a method of treatment or prevention of acute and/or chronic neurological disorders by administering an effective amount of the compound of formula I or a pharmaceuticall acceptable salt thereof.

  这项发明涉及一种二氢苯并[b][1,4]二氮杂烷-2-酮衍生物，其化学式中的R1、R2、R3和Y如规范中所定义。该发明包括含有这些化合物的药物组合物、其制备方法以及通过给予公式I化合物或其药学上可接受的盐的有效量来治疗或预防急性和/或慢性神经系统疾病的方法。
• Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease
  申请人：Kinzel Olaf

  公开号：US20130053380A1

  公开（公告）日：2013-02-28

  The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administrating these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

  本发明提供了孤儿核受体RORγ的调节剂以及通过向需要此类治疗的人类或哺乳动物施用这些新型RORγ调节剂来治疗RORγ介导的疾病的方法。具体而言，本发明提供了公式（1）的化合物及其对映体、二对映异构体、互变异构体、溶剂化物和药学上可接受的盐。